Spyre Therapeutics (NASDAQ: SYRE) — Perfil da empresa, notícias e dados financeiros
Spyre Therapeutics advances healthcare through innovative drug development, aiming to significantly improve patient outcomes in various diseases.
Spyre Therapeutics
Spyre Therapeutics (NASDAQ:SPYR) focuses on advancing healthcare through innovative drug development and therapies with the aim to significantly improve patient outcomes in various disease areas. It leverages cutting-edge research and development practices to create a pipeline of promising treatments. With a commitment to excellence and patient health, Spyre Therapeutics tirelessly works on new projects to address unmet medical needs, aiming to bring revolutionary products to the market. Their objectives include not just commercial success, but also making lasting contributions to medicine and patient care globally.
Resumo
Operações
Produtos e/ou serviços de Spyre Therapeutics
- Development of precision oncology drugs targeting specific genetic mutations in cancer cells.
- Research into novel small molecule inhibitors for the treatment of hard-to-target cancers.
- Collaboration on biomarker-driven clinical trials aiming to optimize patient outcomes.
- Creation of a proprietary drug discovery platform enhancing the identification and development of anticancer agents.
- Investigation into combination therapies that leverage the immune system for cancer treatment.
- Expansion of a diagnostic toolkit to better match patients with effective treatments based on their genetic profile.
equipe executiva do Spyre Therapeutics
- Cameron TurtleCEO & Director
- Scott L. BurrowsChief Financial Officer
- Heidy Abreu King-JonesChief Legal Officer & Corporate Secretary
- Sheldon SloanChief Medical Officer
- Janet Gunzner-TosteSenior Vice President of Operations
- Brian ConnollyChief Technical Officer
- Eric McIntyreSenior Vice President of Finance & Investor Relations
- James MyersSenior Vice President of Quality & Compliance
- Justin LaFountaineSenior Vice President of Corporate Development
- Melissa CooperSenior Vice President of People
Principais indicadores financeiros
Resultados divulgados pela Spyre Therapeutics, em USD.
- Cap. de mercado
- 9,3 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -209,6 mi | -155,2 mi | |
| 886 mil | -208,6 mi | -208 mi | |
| 886 mil | -242,3 mi | -338,8 mi | |
| 2,3 mi | -84,8 mi | -83,8 mi |